Utilizing design of experiments to characterize assay robustness.
暂无分享,去创建一个
Bert Gunter | An Song | Saloumeh Kadkhodayan Fischer | Brian Sue | Houston Gilbert | Kyra J Cowan | Rich Erickson | Reginald Delarosa | Daniel A Coleman | B. Gunter | S. Fischer | A. Song | K. Cowan | R. Erickson | R. Delarosa | Dan Coleman | H. Gilbert | Brian Sue
[1] Francesca Civoli,et al. Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. , 2012, Journal of immunological methods.
[2] Maneesha Altekar,et al. Assay optimization: a statistical design of experiments approach. , 2007, Clinics in laboratory medicine.
[3] Binodh DeSilva,et al. Key elements of bioanalytical method validation for macromolecules , 2007, The AAPS Journal.
[4] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[5] Matthew Troutman,et al. Optimizing ELISAs for precision and robustness using laboratory automation and statistical design of experiments. , 2008, Journal of immunological methods.
[6] J. W. Findlay,et al. Some important considerations for validation of ligand-binding assays. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[7] D Brynn Hibbert,et al. Experimental design in chromatography: a tutorial review. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] Y. Vander Heyden,et al. Comparison of Plackett-Burman and supersaturated designs in robustness testing. , 2007, Analytica chimica acta.
[9] Judy Y Shih,et al. Method transfer for ligand-binding assays: recommendations for best practice. , 2011, Bioanalysis.
[10] Mark Ma,et al. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. , 2009, Journal of pharmaceutical and biomedical analysis.
[11] Afshin Safavi,et al. Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents , 2012, The AAPS Journal.
[12] Wendell C. Smith,et al. Application of experimental design techniques to optimize a competitive ELISA. , 1996, Journal of immunological methods.
[13] R. Plackett,et al. THE DESIGN OF OPTIMUM MULTIFACTORIAL EXPERIMENTS , 1946 .
[14] Daniel Sikkema,et al. Complexities of Clinical Assay Development and Optimization Prior to First-in-Man Immunization Trials – A Description of Immunogenicity Assay Development for the Testing of Samples from a Phase 1 Alzheimer's Vaccine Trial , 2008, Journal of immunoassay & immunochemistry.
[15] S Furlanetto,et al. How experimental design can improve the validation process. Studies in pharmaceutical analysis , 2003, Analytical and bioanalytical chemistry.
[16] Lakshmi Amaravadi,et al. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. , 2011, Journal of immunological methods.
[17] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[18] Bieke Dejaegher,et al. Ruggedness and robustness testing. , 2007, Journal of chromatography. A.